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AKT, a protein kinase frequently hyperactivated in cancer, plays an important role in cell survival and contrib-
utes to tumor cell resistance to cytotoxic therapies. A new study in this issue of Cancer Cell shows that AKT
also induces the accumulation of oxygen radicals, which can be exploited to selectively kill cancer cells
containing high levels of AKT activity.A major goal in current oncology research
aims to comprehensively characterize the
molecular alterations driving cancer initia-
tion and progression, which is expected
to help develop more efficient targeted
therapies. However, it has become clear
in recent years that cell regulation mecha-
nisms are highly dependent on cell type
and cellular context. For instance, onco-
genic signals that normally fuel cancer
progression can, in contrast, contribute
to tumor suppression early in transforma-
tion by triggering senescence or cell-
cycle arrest (Yaswen and Campisi, 2007).
The PI3K/AKT signaling pathway is
thought to play a prominent role in the ini-
tiation and maintenance of human cancer,
as many components of this pathway
have been found to be mutated or ampli-
fied in a broad range of tumors (Yuan
and Cantley, 2008). PI3K is a lipid kinase
that is activated downstream of Ras small
GTPases and receptor tyrosine kinases
(RTKs) (Figure 1). Cooperation between
PI3K and the protein kinases PDK1 and
mTORC2 in turn results in full activation
of the nodal serine/threonine protein
kinase AKT, also known as PKB. There
are three mammalian AKT family mem-
bers (Akt1, Akt2, and Akt3), which are
broadly expressed and play key roles in
the regulation of cell growth, proliferation,
and oncogenesis (Skeen et al., 2006).
Conversely, the lipid phosphatase PTEN
functions as a tumor suppressor by an-
tagonizing PI3K activity and inhibiting
the AKT pathway.
In contrast to the well-established, pro-
tumorigenic role of AKT, Nogueira et al.
(2008) report in this issue of Cancer Cell
the unexpected implication of AKT in trig-
gering the process of cellular senescence,
one of the earliest barriers against celltransformation (Collado et al., 2007). The
authors focus on a less-characterized cel-
lular function of the PI3K/AKT pathway,
the induction of intracellular reactive oxy-
gen species (ROS), which have been as-
sociated with pathological effects when
accumulated to high levels (Finkel, 2003).
Nogueira et al. show that ROS produc-
tion by AKT sensitizes primary mouse and
human fibroblasts to replicative senes-
cence, the process by which cells stop di-
viding after a limited number of passages
in culture, as well as to Ras-induced pre-
mature senescence, in agreement with
the role of ROS as mediators of cellular
aging (Yaswen and Campisi, 2007). Ac-
cordingly, primary mouse fibroblasts defi-
cient in Akt1 and Akt2 (Akt1/2) contained
lower ROS levels and were more resistant
to passage- or oncogene-induced senes-
cence. Thus, AKT appears to be a novel
regulator of life span in mammalian cells,
as has previously been proposed for the
ERK1/2 and p38 MAP kinases (Collado
et al., 2007). These results also imply
that AKT activation might only exert its
full transforming potential after evading
the senescence response induced by
ROS, in line with previous reports (Chen
et al., 2005).
So, how does AKT activity raise ROS
levels? Previous studies have implicated
Ras proteins in the regulation of intracellu-
lar ROS production, mainly through the
ERK1/2 and Rac signaling pathways
(Dolado et al., 2007; Trachootham et al.,
2006). Nogueira et al. now show that
AKT is also a key mediator of Ras-induced
ROS by engaging two different mecha-
nisms (Figure 1). One capitalizes on the
evolutionarily conserved role of AKT as
a stimulator of glycolysis and oxidative
metabolism (Plas and Thompson, 2005).Cancer Cell 14,The authors show that AKT stimulates
oxidative metabolism in the mitochondria
concurrent with enhanced oxygen con-
sumption, which indirectly increases in-
tracellular ROS. Importantly, the reduced
mitochondrial activity observed in Akt1/2
double-knockout cells does not seem to
be a consequence of impaired prolifera-
tion, supporting that AKT directly regu-
lates metabolic enzymes.
An additional mechanism by which AKT
can induce ROS accumulation involves
the direct phosphorylation and exclusion
from the nucleus of the forkhead box O
(FoxO) family of transcription factors (Fig-
ure 1). Nogueira et al. present several lines
of evidence supporting that FoxO inhibi-
tion is important for AKT-induced ROS
accumulation and senescence. They also
confirm previous work showing that FoxO
induces the transcriptional expression
of the antioxidant enzymes manganese
superoxide dismutase (MnSOD) and cat-
alase and identify sestrin 3 (Sesn3) as
a new FoxO target gene with antioxidant
activity. Accordingly, Sesn3, MnSOD, and
catalase were all expressed at higher
levels in Akt1/2-deficient fibroblasts, con-
tributing to their lower levels of ROS. Of
note, Sesn3 downregulation restored ROS
levels and the senescence response of
Akt1/2-deficient cells close to wild-type
levels, suggesting a key role for this en-
zyme in ROS detoxification. In summary,
enhanced mitochondrial activity together
with reduced antioxidant defenses via
FoxO inhibition seems to account for the
ability of AKT to induce ROS.
Incontrast to primary cells, immortalized
and tumorigenic cell lines are generally re-
fractory to ROS-induced senescence, as
this response requires regulatory path-
ways that are usually inactivated duringDecember 9, 2008 ª2008 Elsevier Inc. 427
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Under normal conditions (middle panel), AKT increases intracellular reactive oxygen species (ROS) levels by stimulating oxidative metabolism in the mitochondria
and also by repressing, via FoxO phosphorylation and sequestration in the cytoplasm, the transcription of genes encoding antioxidant enzymes, of which sestrin 3
(Sesn3) appears to play a prominent role. These mechanisms probably contribute to homeostatic cell regulation. When AKT signaling is downregulated (left
panel), ROS levels are reduced due to both decreased mitochondrial activity and increased FoxO-mediated expression of antioxidant enzymes. Conversely,
AKT hyperactivation (right panel), as occurs in many cancer cell types, raises metabolic activity in the mitochondria and inhibits FoxO transcriptional activity,
resulting in highly increased ROS levels. The upregulation of ROS in turn promotes senescence in primary cells and sensitizes cancer cells to apoptosis induced
by oxidative stimuli. RTK, receptor tyrosine kinase; LOH, loss of heterozygosity.transformation (Collado et al., 2007). Con-
sequently, ROS tend to accumulate in
these cells and promote carcinogenesis,
except when ROS reach a certain thresh-
old that irreversibly leads to cell death (Tra-
chootham et al., 2006). This double-edged
effect of oxidative stress has led to the idea
that forced accumulation of ROS might
have therapeutic applications (Trachoo-
tham et al., 2006); since cancer cells nor-
mally contain higher levels of ROS than
nontransformed cells, they should be
more sensitive to oxidative stimuli.
Importantly, Nogueira et al. also pro-
vide evidence, based on both cell cultures
and subcutaneous xenografts in mice,
supporting the idea that cells with en-
hanced AKT activity may be selectively
killed due to their higher sensitivity to
ROS-induced apoptosis. They show that
high levels of AKT activity and ROS pre-
dispose immortalized murine fibroblasts
as well as human cancer cells derived
from glioblastoma and ovarian tumors to428 Cancer Cell 14, December 9, 2008 ª200selective killing by pro-oxidant stimuli,
such as hydrogen peroxide or the antiox-
idant-depleting drug phenylethyl isothio-
cyanate (PEITC) (Trachootham et al.,
2006). The in vivo results of Nogueira
et al. are particularly noteworthy, as sub-
cutaneous tumors formed by injection of
mice with ovarian cancer cells containing
hyperactive AKT were shown to regress
completely upon PEITC treatment. Con-
versely, and in agreement with the
well-established prosurvival role of AKT
reported by many other groups, AKT hy-
peractivation induced resistance to drugs
that do not function primarily by enhanc-
ing ROS levels, such as the topoisomer-
ase inhibitor etoposide.
Given that upregulation of the PI3K/
AKT pathway is one of the most prevalent
alterations in human cancer, there is
much interest in the development of inhib-
itors to target this signaling pathway
(Garcia-Echeverria and Sellers, 2008).
However, existing drugs against various8 Elsevier Inc.components of the PI3K/AKT pathway
have shown either limited clinical success
or intolerable side toxicity, perhaps due to
the conserved role of PI3K/AKT signaling
in glucose metabolism in normal cells.
Interestingly, the work by Nogueira et al.
suggests a new approach to target can-
cer cells with high AKT activity levels,
which exploits the ability of AKT to pro-
mote ROS accumulation in order to in-
duce apoptosis via oxidant stimuli. These
observations also imply that high ROS
levels somehow overcome the prosurvival
signaling by AKT, which normally contrib-
utes to tumor cell viability. Further studies
addressing how ROS evade AKT-induced
cell survival might widen the therapeutic
opportunities to targetapoptosis-refractory
human tumors bearing active AKT.
Overall, the study by Nogueira et al.
supports previous evidence indicating
that therapies based on the induction of
oxidative stress might be beneficial for
the treatment of human tumors containing
Cancer Cell
Previewshigh levels of ROS. This could be further
potentiated by combination with drugs
that modulate specific signal transduction
pathways. Future work should concen-
trate on identifying appropriate oxidative
biomarkers as well as ROS-modulating
drugs to address this possibility clinically.
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Infantile hemangiomas are benign local-
ized lesions, comprised primarily of aber-
rant endothelial cells (ECs), that appear
within the first weeks of life. These lesions
go through a proliferation phase during the
first 6–10 months and slowly regress over
the following 5–10 years. During the invo-
lution phase, the vasculature undergoes
apoptosis and is replaced by fibrotic fatty
tissue. Depending on their location, hem-
angiomas can cause deformity or life-
threatening complications (Barnes et al.,
2007). Previously, Olsen and colleagues
isolated hemangioma ECs (hemECs)
from actively proliferating angiomas of
nine unrelated infants and showed that
these lines were clonal, arising from a
single progenitor cell (Boye et al., 2001).
These cells are thought to originate from
placental ECs or to be differentiated to-
ward the placental microvascular pheno-
type (Barnes et al., 2007). Although their
origin is uncertain, hemECs have a charac-
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maintained in cultured cells and differs
from those of normal ECs. They have
increased rates of proliferation and en-
hanced VEGF-mediated migration (Boye
et al., 2001). However, until now, the mo-
lecular mechanisms driving the aberrant
behavior of hemECs remained unknown.
In a recent study, Jinnin et al. (2008)
showed that VEGFR2 signaling is constitu-
tively active in cultured hemECs due to de-
creased VEGFR1 expression. Since both
receptorsbindVEGF-A,VEGFR1 is thought
to negatively regulate VEGFR2 signaling by
acting as a decoy receptor for VEGF-A
(Olsson et al., 2006). Therefore, constitutive
VEGFR2 activity due to suppression of
VEGFR1 could explain the increased prolif-
eration and migration of hemECs.
With this in mind, the authors delved
further into how VEGFR1 is regulated in
hemECs as compared to normal ECs. Be-
cause both VEGFR1 (FLT1) transcript and
protein levels were minimal in hemECs,
Jinnin et al. sequenced part of the FLT1
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cell (EC) origin, yet the mechanisms
y by Jinnin et al. demonstrates that
ion of NFAT (nuclear factor of acti-
promoter from all nine hemEC lines.
They demonstrated that a region of the
FLT1 promoter contains a binding site for
the transcription factor NFAT, providing
the first evidence that FLT1 represents
an NFAT target gene. Functionally, this
finding was critical to the characterization
of hemECs because the authors also dem-
onstrated that NFAT transcriptional activ-
ity is lower in hemECs than in normal
ECs. Hence, suppression of NFAT-depen-
dent FLT1 transcription could help drive
the enhanced VEGF signaling of hemECs.
Looking upstream of NFAT to a cell-
surface receptor, Jinnin et al. also found
that reduced NFAT activation in hemECs
was associated with decreased b1 integ-
rin activity and decreased adhesion to
the b1 integrin substrates type I collagen
and fibronectin, despite equivalent sur-
face expression of b1 integrin between
both cell types.
Previous studies suggested a genetic
link between hemangioma growth and
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